Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis

Imaan Benmerzouga, Lisa A. Checkley, Michael T. Ferdig, Gustavo Arrizabalaga, Ronald Wek, William Sullivan

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Toxoplasma gondii is a protozoan parasite that persists as a chronic infection. Toxoplasma evades immunity by forming tissue cysts, which reactivate to cause life-threatening disease during immune suppression. There is an urgent need to identify drugs capable of targeting these latent tissue cysts, which tend to form in the brain. We previously showed that translational control is critical during infections with both replicative and latent forms of Toxoplasma. Here we report that guanabenz, an FDA-approved drug that interferes with translational control, has antiparasitic activity against replicative stages of Toxoplasma and the related apicomplexan parasite Plasmodium falciparum (a malaria agent). We also found that inhibition of translational control interfered with tissue cyst biology in vitro. Toxoplasma bradyzoites present in these abnormal cysts were diminished and misconfigured, surrounded by empty space not seen in normal cysts. These findings prompted analysis of the efficacy of guanabenz in vivo by using established mouse models of acute and chronic toxoplasmosis. In addition to protecting mice from lethal doses of Toxoplasma, guanabenz has a remarkable ability to reduce the number of brain cysts in chronically infected mice. Our findings suggest that guanabenz can be repurposed into an effective antiparasitic with a unique ability to reduce tissue cysts in the brain.

Original languageEnglish (US)
Pages (from-to)6939-6945
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Guanabenz
Antiparasitic Agents
Toxoplasmosis
Toxoplasma
Cysts
Brain
Parasites
Falciparum Malaria
Immune System Diseases
Drug Delivery Systems
Infection
Immunity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis. / Benmerzouga, Imaan; Checkley, Lisa A.; Ferdig, Michael T.; Arrizabalaga, Gustavo; Wek, Ronald; Sullivan, William.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 11, 01.11.2015, p. 6939-6945.

Research output: Contribution to journalArticle

@article{ebd4a49ce4ed42728a6e61575c715c8e,
title = "Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis",
abstract = "Toxoplasma gondii is a protozoan parasite that persists as a chronic infection. Toxoplasma evades immunity by forming tissue cysts, which reactivate to cause life-threatening disease during immune suppression. There is an urgent need to identify drugs capable of targeting these latent tissue cysts, which tend to form in the brain. We previously showed that translational control is critical during infections with both replicative and latent forms of Toxoplasma. Here we report that guanabenz, an FDA-approved drug that interferes with translational control, has antiparasitic activity against replicative stages of Toxoplasma and the related apicomplexan parasite Plasmodium falciparum (a malaria agent). We also found that inhibition of translational control interfered with tissue cyst biology in vitro. Toxoplasma bradyzoites present in these abnormal cysts were diminished and misconfigured, surrounded by empty space not seen in normal cysts. These findings prompted analysis of the efficacy of guanabenz in vivo by using established mouse models of acute and chronic toxoplasmosis. In addition to protecting mice from lethal doses of Toxoplasma, guanabenz has a remarkable ability to reduce the number of brain cysts in chronically infected mice. Our findings suggest that guanabenz can be repurposed into an effective antiparasitic with a unique ability to reduce tissue cysts in the brain.",
author = "Imaan Benmerzouga and Checkley, {Lisa A.} and Ferdig, {Michael T.} and Gustavo Arrizabalaga and Ronald Wek and William Sullivan",
year = "2015",
month = "11",
day = "1",
doi = "10.1128/AAC.01683-15",
language = "English (US)",
volume = "59",
pages = "6939--6945",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis

AU - Benmerzouga, Imaan

AU - Checkley, Lisa A.

AU - Ferdig, Michael T.

AU - Arrizabalaga, Gustavo

AU - Wek, Ronald

AU - Sullivan, William

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Toxoplasma gondii is a protozoan parasite that persists as a chronic infection. Toxoplasma evades immunity by forming tissue cysts, which reactivate to cause life-threatening disease during immune suppression. There is an urgent need to identify drugs capable of targeting these latent tissue cysts, which tend to form in the brain. We previously showed that translational control is critical during infections with both replicative and latent forms of Toxoplasma. Here we report that guanabenz, an FDA-approved drug that interferes with translational control, has antiparasitic activity against replicative stages of Toxoplasma and the related apicomplexan parasite Plasmodium falciparum (a malaria agent). We also found that inhibition of translational control interfered with tissue cyst biology in vitro. Toxoplasma bradyzoites present in these abnormal cysts were diminished and misconfigured, surrounded by empty space not seen in normal cysts. These findings prompted analysis of the efficacy of guanabenz in vivo by using established mouse models of acute and chronic toxoplasmosis. In addition to protecting mice from lethal doses of Toxoplasma, guanabenz has a remarkable ability to reduce the number of brain cysts in chronically infected mice. Our findings suggest that guanabenz can be repurposed into an effective antiparasitic with a unique ability to reduce tissue cysts in the brain.

AB - Toxoplasma gondii is a protozoan parasite that persists as a chronic infection. Toxoplasma evades immunity by forming tissue cysts, which reactivate to cause life-threatening disease during immune suppression. There is an urgent need to identify drugs capable of targeting these latent tissue cysts, which tend to form in the brain. We previously showed that translational control is critical during infections with both replicative and latent forms of Toxoplasma. Here we report that guanabenz, an FDA-approved drug that interferes with translational control, has antiparasitic activity against replicative stages of Toxoplasma and the related apicomplexan parasite Plasmodium falciparum (a malaria agent). We also found that inhibition of translational control interfered with tissue cyst biology in vitro. Toxoplasma bradyzoites present in these abnormal cysts were diminished and misconfigured, surrounded by empty space not seen in normal cysts. These findings prompted analysis of the efficacy of guanabenz in vivo by using established mouse models of acute and chronic toxoplasmosis. In addition to protecting mice from lethal doses of Toxoplasma, guanabenz has a remarkable ability to reduce the number of brain cysts in chronically infected mice. Our findings suggest that guanabenz can be repurposed into an effective antiparasitic with a unique ability to reduce tissue cysts in the brain.

UR - http://www.scopus.com/inward/record.url?scp=84946078602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946078602&partnerID=8YFLogxK

U2 - 10.1128/AAC.01683-15

DO - 10.1128/AAC.01683-15

M3 - Article

C2 - 26303803

AN - SCOPUS:84946078602

VL - 59

SP - 6939

EP - 6945

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -